IRMD IRADIMED CORP

CIK 0001325618 47 ready 8-Ks latest July 31, 2026, 8:15 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 47

Latest filing August 18, 2026, 2:03 PM ET

Top materiality 0.80

Event mix earnings ×24 · other_material ×10 · leadership ×5

Sentiment 29 pos · 1 neg · 17 neu

Latest earnings ▲ beat 2026-Q2

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for IRMD

Highest-materiality recent filing

Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

May 1, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.

Read filing →

July 31, 2026, 8:15 AM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Iradimed Q2 revenue flat at $20.5M, EPS down; declares $0.20 dividend; reaffirms FY guidance

Q2 revenue $20.5M (+0.5% YoY); GAAP EPS $0.41 (down from $0.45); non-GAAP EPS $0.46 (down from $0.49).
May 1, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
February 10, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Iradimed reports record Q4 revenue $22.7M, EPS $0.50; raises dividend to $0.20

Q4 2025 revenue $22.7M (+17% YoY); GAAP diluted EPS $0.50 (+25%), non-GAAP $0.54 (+23%).
December 8, 2025, 6:59 PM ET dividend materiality 0.65 positive item 8.01 item 9.01

iRadimed declares special cash dividend of $0.50 per share

Special dividend of $0.50 per share payable Dec 30, 2025 to holders of record Dec 17, 2025.
November 3, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance

GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).
August 1, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance

GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).
May 29, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

iRadimed receives FDA 510(k) clearance for next-gen MRidium 3870 infusion pump

FDA granted 510(k) clearance on May 29, 2025 for the MRidium 3870 IV Infusion Pump System.
May 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Iradimed Q1 record revenue $19.5M (+11% YoY); EPS $0.37 GAAP, $0.42 non-GAAP

Record Q1 revenue of $19.5M, up 11% YoY from $17.6M; GAAP diluted EPS $0.37 (+16% YoY).
February 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

IRADIMED Q4 revenue $19.4M (+11% YoY); raises quarterly dividend to $0.17/share

Q4 revenue record $19.4M (+11% YoY); GAAP EPS $0.40, non-GAAP EPS $0.44.
January 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY

Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.
October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend

Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.
August 1, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38

Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.
May 2, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP

Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.
February 8, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M

Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.
December 12, 2023, 6:59 PM ET dividend materiality 0.65 positive item 8.01 item 9.01

Iradimed initiates $0.15 quarterly dividend and $0.48 special cash dividend

Special dividend of $0.48 per share (~$6.1M); quarterly dividend of $0.15 per share (~$1.9M) initiated.
November 3, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×4

Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37

Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.
August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

IRADIMED reports record Q2 revenue of $16.1M, raises FY2023 guidance

Q2 revenue $16.1M (+25% YoY); GAAP diluted EPS $0.33 vs $0.26; non-GAAP EPS $0.36 vs $0.26.
May 4, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

IRADIMED reports record Q1 revenue $15.5M; raises FY 2023 guidance

Q1 revenue $15.5M (+25.7% YoY); GAAP diluted EPS $0.27, non-GAAP $0.30.
February 3, 2023, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 9.01 ◈ Material Agreements

iRadimed reinstates land purchase, acquires 26.5 acres in Florida for $6.2M for new manufacturing facility

Purchased ~26.518 acres in Orange County, FL for $6.2M from O Property, Ltd.
February 2, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×4

iRadimed Q4 revenue $14.9M (+25% YoY); declares special $1.05 dividend; FY23 guidance $61-63M

Q4 2022 revenue $14.9M (vs $11.9M Q4 2021); GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.32.
January 19, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

iRadimed reports preliminary Q4 revenue $14.9M (+25% YoY); issues FY2023 guidance $61M-$63M

Q4 2022 preliminary revenue $14.9M, up 25% YoY, above guidance of $14.1M-$14.8M.
November 4, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings◈ Material Agreements

Iradimed agrees to buy 27.19 acres in Florida for $7.3M for new facility

Purchase price of $7.3M for approximately 27.19 acres of land in Orange County, FL.
November 3, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

iRadimed Q3 revenue up 23% to $13.4M; GAAP EPS $0.27; guides Q4 rev $14.1-14.8M

Q3 revenue $13.4M (+23% YoY), operating income $4.1M (+32%), GAAP EPS $0.27 (+35%).
October 11, 2022, 7:59 PM ET regulatory materiality 0.70 neutral item 2.02 item 8.01 item 9.01

Iradimed withdraws 510(k) for MRidium 3870 pump; Q3 revenue $13.4M beats guidance

Voluntarily withdrew 510(k) for MRidium 3870 Infusion Pump on Oct 5; plans to resubmit after FDA talks.
July 29, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

iRadimed reports record Q2 revenue of $12.7M; GAAP EPS $0.26; full-year guidance raised

Q2 revenue $12.7M vs $9.8M YoY (+30%); GAAP diluted EPS $0.26 vs $0.12; non-GAAP EPS $0.26.
May 26, 2022, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

iRadimed appoints John (Jack) Glenn as CFO effective June 20, 2022

Salary $340,000/year, eligible for annual bonus of 50% of salary.
April 29, 2022, 7:59 PM ET leadership materiality 0.60 negative item 5.02 item 9.01 ◈ executive_change ×2

iRadimed CFO/COO Resigns; Controller Named Interim CFO

Chris Scott, CFO and COO, resigns effective May 27, 2022 to pursue other opportunities.
April 29, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

iRadimed Q1 revenue $12.3M (+33% YoY), EPS $0.20; raises FY22 guidance

Q1 revenue $12.3M vs $9.2M YoY; GAAP diluted EPS $0.20 vs $0.11; non-GAAP EPS $0.22 vs $0.13.
February 7, 2022, 6:59 PM ET dividend materiality 0.65 positive item 8.01 item 9.01

iRadimed declares special $1.00 per share cash dividend

Special cash dividend of $1.00 per share declared by Board on Feb 5, 2022.
February 4, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M

Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.
October 29, 2021, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

iRadimed Q3 revenue up 42% to $10.9M; raises full-year guidance

Q3 2021 revenue $10.9M (+42% YoY); GAAP diluted EPS $0.20, non-GAAP $0.23.
July 30, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M

Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.

Executive changes

Appointed

Hilda Scharen-Guivel

Director

IRMD · IRADIMED CORP

Effective: 2022-10-04
Filed: October 6, 2022, 7:59 PM ET

elected Ms. Hilda Scharen-Guivel as a Director, both effective October 4, 2022.

Appointed

John (Jack) Glenn

Chief Financial Officer

IRMD · IRADIMED CORP

Effective: 2022-06-20
Filed: May 26, 2022, 7:59 PM ET

On May 26, 2022, iRadimed Corporation (the “Company”) issued a press release announcing the appointment of John (Jack) Glenn as Chief Financial Officer of the Company, effective on or before June 20, 2022.

Departed

Chris Scott

Chief Financial and Operating Officer

IRMD · IRADIMED CORP

Effective: 2022-05-27
Successor: Matt Garner
Filed: April 29, 2022, 7:59 PM ET

announcing the resignation of Chris Scott, Chief Financial and Operating Officer of iRadimed Corporation (the “Company”), effective May 27, 2022.

Appointed (interim)

Matt Garner

interim Chief Financial Officer

IRMD · IRADIMED CORP

Effective: 2022-04-28
Filed: April 29, 2022, 7:59 PM ET

has appointed Matt Garner, Controller, to serve as interim Chief Financial Officer, effective April 28, 2022.

Role change

Chris Scott

Chief Financial and Operating Officer

IRMD · IRADIMED CORP

Effective: 2021-07-08
Filed: July 12, 2021, 7:59 PM ET

On July 8, 2021, Iradimed Corporation (the “Company”) appointed Chris Scott, 51, as its Chief Financial and Operating Officer effective immediately.

Earnings & guidance

2026-Q2 EPS reported $0.86 vs consensus $0.43 ▲ beat (+100.7%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

29 positive 1 negative 17 neutral

source · IRMD on sec.gov